Spring LM, Tolaney SM, Fell G, Bossuyt V, et al. Response-guided neoadjuvant sacituzumab govitecan for localized triple negative breast cancer: results from the NeoSTAR trial. Ann Oncol 2023 Dec 11:S0923-7534(23)05107-4. doi: 10.1016/j.annonc.2023.
PMID: 38092228